Navigation Links
338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
Date:9/4/2008

SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced that the pivotal clinical study of Polidocanol, conducted in Germany by BioForm Medical's partner, Chemische Fabrik KREUSSLER & Co. GmbH (Kreussler), successfully met the study primary endpoint and has been submitted to FDA as part of a New Drug Application (NDA) process.

In the pivotal clinical study, named the EASI (Efficacy and safety of Aethoxysklerol compared to Sodium Tetradecyl Sulfate and Isotonic Saline) study, 338 patients with C1 varicose veins (either spider veins of <1mm diameter or reticular veins of 1-3mm diameter), were randomized to receive either Polidocanol (also called Lauromacrogol 400, European tradename, Aethoxysklerol(R)), Sodium-tetradecyl-sulfate (STS or Sotradecol(R), an effective control), or Isotonic saline (a placebo control). Patients were followed for 26 weeks (6 months) with standardized photography of a defined 10x10 cm area of the leg at baseline, 12 weeks and 26 weeks. These photographs were rated by the treating physicians and two blinded evaluators, which served as the basis for efficacy assessment.

The EASI study successfully met its primary efficacy endpoint with demonstrated statistically significant superiority (p<0.0001) of Polidocanol versus placebo. The treatment success rates for Polidocanol were 96% and 95% at 12 and 26 weeks, compared to STS (92%, 91%) and placebo (8%, 6%). A secondary endpoint analysis demonstrated that significantly more patients were satisfied or very satisfied with Polidocanol at 12 or 26 weeks (88%, 84%), compared to STS (63%, 64%; p<0.0001) or placebo (13%, 11%; p<0.0001). Polidocanol was found to be safe and well tolerated in the study. The incidence
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Agendia Launches TargetPrint(R) for Breast Cancer Patients
4. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
5. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
6. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
7. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
9. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
10. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
11. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
(Date:7/30/2014)... VILLAGE, Nev. , July 30, 2014  PDL ... announced that company management will participate in the Jefferies ... Boston , Massachusetts. The conference will occur on August ... About PDL BioPharma, Inc. PDL BioPharma manages ... of its Queen et al. antibody humanization patents and ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
... Oct. 26, 2011 Reportlinker.com announces ... is available in its catalogue: ... Pharmaceutical R&D: Company strategies, emerging markets ... http://www.reportlinker.com/p0114851/Key-Trends-in-Offshoring-Pharmaceutical-RD-Company-strategies-emerging-markets-and-impact-on-ROI.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 2Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 3Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 4Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 5Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 6Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 7Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 8Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 9
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- It can happen ... television, dresser or computer monitor and gets critically injured ... of a young child should look around their homes and ... a child. Imagining it is better than it becoming a ... Emergency Physicians, said in a college news release. Between ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Visitors to ... contributed over $8,500 to ensure its protection. Bob Kiesendahl, ... a check to the Delaware Highlands Conservancy for donations ... The small $2-per-stay donations add up fast, as visitors ... the Upper Delaware River Region. , The Kiesendahl family ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
(Date:7/30/2014)... ... ... ... , UCLA ... For the study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. ...
Breaking Medicine News(10 mins):Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... A University of Melbourne study has revealed that certain ... link between mammographic breast density and breast cancer. ... Health says women vary greatly in their underlying risk ... possible new pathways into the development of breast cancer." ...
... Del.Feb. 16, 2010 Cancer , the peer-reviewed international ... a study conducted by HealthCore, Inc. in its ... treatment between commercially insured African-American and white women. ... of previous studies conducted in populations using ...
... team of researchers has found that adding a humanized monoclonal ... new or enlarged brain lesions in patients with relapsing multiple ... and in the March edition of the Lancet Neurology ... which the body,s immune system attacks the fatty substance that ...
... Celebrity ... will be awarded $5,000 for best eye care tips., , ... Atlanta, GA (Vocus) February 16, 2010 -- Just as people ... the AIR OPTIX AQUA brand team is partnering with Carmindy, makeup artist on TLC’s hit ...
... with the worst cases report the fewest nightmares, study finds ... that accompany severe sleep apnea may be counterbalanced by this ... , "We found that people with significant sleep apnea have ... fewer nightmares," said Dr. Jim Pagel, lead author of a ...
... ... the use of social tools. , ... Minneapolis, MN (PRWEB) February 16, 2010 -- BusinessCard2 ™, a ... of the Social Business Innovation Awards. The competition was established to recognize great ...
Cached Medicine News:Health News:Study reveals genetic link between mammographic density and breast cancer 2Health News:Cancer publishes study confirming disparity in breast cancer treatment 2Health News:Promising therapy for relapsing multibple sclerosis 2Health News:Promising therapy for relapsing multibple sclerosis 3Health News:CIBA VISION Partners with TLC's Carmindy to Educate Consumers About Healthy Eye Habits 2Health News:CIBA VISION Partners with TLC's Carmindy to Educate Consumers About Healthy Eye Habits 3Health News:CIBA VISION Partners with TLC's Carmindy to Educate Consumers About Healthy Eye Habits 4Health News:Severe Sleep Apnea Has Silver Lining 2Health News:Severe Sleep Apnea Has Silver Lining 3Health News:BusinessCard2 Wins Social Business Innovation Award 2Health News:BusinessCard2 Wins Social Business Innovation Award 3
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: